目的：比较0.01%和0.05%阿托品滴眼液控制青少年近视的疗效。

方法：于2021-10/2023-02选取本院收治的108例青少年近视患者(均只分析右眼数据)，随机分为观察组、对照组各54例54眼。所有患儿均配戴全矫单焦框架眼镜矫正屈光不正。对照组患者使用0.01%阿托品滴眼液，观察组患者使用0.05%阿托品滴眼液。比较两组患者治疗前，治疗4、12 mo后眼轴长度(AL)、瞳孔直径、等效球镜度(SE)、调节幅度的变化情况以及不适症状的发生情况。

结果：与治疗前相比，治疗后两组患者的AL、瞳孔直径均增大，SE、调节幅度降低(均P<0.05)。治疗后观察组AL小于对照组，瞳孔直径、SE大于对照组(均P<0.05)。用药初期，对照组6眼(11.8%)、观察组15眼(28.8%)出现畏光现象(室外强光)，且观察组2眼出现视近模糊症状，两组不适症状比较有差异(χ²=6.502，P=0.011)。

结论：0.05%阿托品滴眼液对青少年近视控制效果较好，但对瞳孔直径的影响较大，不适症状的发生风险更高。

METHODS:A total of 108 adolescents with myopia admitted to our hospital from October 2021 to February 2023 were selected and randomly divided into 54 cases each in the observation group and the control group. All patients wore full-corrected monofocal frame glasses for the correction of refractive error. Patients in the control group used 0.01% atropine eye drops, and patients in the observation group used 0.05% atropine eye drops. The changes of the axial length(AL), pupil diameter, spherical equivalent(SE), amplitude of accommodation, as well as the occurrence of discomfort symptoms were compared between the two groups of patients before treatment and at 4 and 12 mo after treatment.

RESULTS: Compared with the pre-treatment period, the AL and pupil diameter of both groups increased, and the SE and amplitude of accommodation decreased after treatment(all P<0.05). The AL of the observation group was smaller than that of the control group, and the pupil diameter and SE were larger than that of the control group after treatment(all P<0.05). At the beginning of medication, 6 eyes(11.8%)in the control group and 15 eyes(28.8%)in the observation group showed photophobia(outdoor bright light), and 2 eyes in the observation group showed blurred vision, and there was a difference in the comparison of the discomfort symptoms between the two groups(χ²=6.502, P=0.011).

CONCLUSION:0.05% atropine eye drops are more effective in controlling myopia in adolescents, but have a greater influence on pupil diameter and a higher risk of discomfort.